banner

The official advocacy organization for pharmacist women in the United States

Pharmacist Moms Group

45,000+ Members

45,000+ Members

Over 6 Million posts, comments and reactions in 2020

Over 6 Million posts, comments and reactions in 2020

60,000+ Followers on social media platforms

60,000+ Followers on social media platforms

The Largest Community of Women Pharmacists in the US

pharmacist moms

Founded in 2017, Pharmacists Moms Group was created to provide women pharmacists the opportunity to network, collaborate and offer genuine feedback in a closed-door, trusted setting. The organization has quickly grown to over 45,000 members and 60,000 followers on our social media platforms.

Pharmacy News
View More
Nivolumab-Chemotherapy Combination Lengthens Survival, Causes Manageable Adverse Effects in Stage III or IV Classic Hodgkin Lymphoma

Compared with brentuximab vedotin and chemotherapy, nivolumab and chemotherapy had longer progression-free survival and a better safety profile.

Study Finds Ezetimib, Rifampin May Increase Coproporphyrin Concentrations in Healthy Patients

The researchers observe that the combination treatment results in higher serum levels compared with ezetimibe alone.

FDA Approves Sodium Oxybate to Treat Cataplexy or EDS in Pediatric Patients With Narcolepsy

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

Removing Mesna From Cyclophosphamide Cycles in VAdriaC-IE for Ewing Sarcoma

This retrospective cohort study provides preliminary evidence for safe removal of mesna from VAdriaC cycles, as the incidence of hemorrhagic cystitis did not increase in patients with Ewing sarcoma who received cyclophosphamide without prophylactic mesna.

Unmasking Health Care Fraud: RICO Is Increasingly Being Used in the Pharmaceutical Industry

RICO is being leveraged in the pharmaceutical industry with significant implications for insurers and public trust.

Emerging HER2-Targeted Therapies in NSCLC: Zongertinib and BAY 2927088

HER2-mutant NSCLC is associated with poor prognosis. Zongertinib and BAY 2927088 are HER2 tyrosine kinase inhibitors that have activity in NSCLC with manageable toxicity profiles.

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy